Tocagen Inc (NASDAQ:TOCA) was the target of some unusual options trading activity on Wednesday. Investors acquired 1,475 put options on the stock. This represents an increase of 1,436% compared to the average daily volume of 96 put options.

Several brokerages have recently weighed in on TOCA. Citigroup set a $14.00 target price on shares of Coty and gave the company a “hold” rating in a research note on Thursday, May 30th. Zacks Investment Research upgraded shares of Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research note on Friday, June 28th. Leerink Swann set a $5.00 target price on shares of Tocagen and gave the company a “hold” rating in a research note on Wednesday, May 22nd. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Finally, Svb Leerink began coverage on shares of Tocagen in a research note on Monday, April 15th. They issued a “market perform” rating and a $11.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.08.

TOCA opened at $5.78 on Friday. The firm has a market capitalization of $137.46 million, a PE ratio of -2.37 and a beta of 3.92. The company has a fifty day moving average of $5.62. The company has a quick ratio of 5.05, a current ratio of 5.05 and a debt-to-equity ratio of 0.75. Tocagen has a 12-month low of $4.13 and a 12-month high of $15.80.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $2.01 million. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. On average, sell-side analysts predict that Tocagen will post -2.94 earnings per share for the current year.

In other news, Director Faheem Hasnain bought 43,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was acquired at an average cost of $4.66 per share, for a total transaction of $200,380.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 53,000 shares of company stock valued at $244,880 over the last 90 days. Insiders own 10.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sphera Funds Management LTD. acquired a new position in Tocagen during the first quarter valued at approximately $1,304,000. Rubric Capital Management LP acquired a new position in Tocagen during the first quarter valued at approximately $1,176,000. Acadian Asset Management LLC grew its holdings in Tocagen by 5,736.6% during the first quarter. Acadian Asset Management LLC now owns 36,829 shares of the company’s stock valued at $401,000 after purchasing an additional 36,198 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Tocagen by 19.0% during the first quarter. JPMorgan Chase & Co. now owns 453,391 shares of the company’s stock valued at $4,929,000 after purchasing an additional 72,539 shares during the last quarter. Finally, Beaumont Financial Partners LLC grew its holdings in Tocagen by 10.4% during the first quarter. Beaumont Financial Partners LLC now owns 14,999 shares of the company’s stock valued at $163,000 after purchasing an additional 1,413 shares during the last quarter. 34.88% of the stock is currently owned by hedge funds and other institutional investors.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: What is the Difference Between Common Shares and Convertible Shares?

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.